乐
乐观
乐观 · 25%CMMB
$1.23
情景价格
$1.380
+0.143 (+10.39%)收盘时
Loading chart…
- 最高
- 1.380
- 开盘
- 1.270
- 成交量加权均价
- 1.34
- 成交量
- 59.32K
- 市值
- 13.81M
- 最低
- 1.250
- 成交额
- 79.28K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
AI 分析 of Chemomab Therapeutics Ltd (CMMB)
买入Chemomab Therapeutics Ltd. (CMMB) appears to be a good buy right now, trading at $1.38, which is significantly below its 52-week high of $2.99, indicating potential upside. The stock has shown a strong 5-day change of +18.96%, suggesting positive momentum. However, the company has a negative net income with losses reaching -2,165,000 USD in Q2 2026, which presents a risk to consider.
估值指标
Chemomab Therapeutics Ltd（CMMB）当前预期市盈率为 12.94，5 年平均预期市盈率为 -15.29。
Alphio AI 对 CMMB 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
8.508-19NewsfilterChemomab and Scipher Merger Progressing
7.507-10NASDAQ.COMKey Developments in Biotech Sector This Week
8.507-08seekingalphaChemomab and Scipher Enter Definitive Merger Agreement
- 8.507-08Newsfilter
Chemomab and Scipher Merge to Advance RA Drug Development
2.007-03NASDAQ.COMBiotech Companies See Significant Stock Gains
CMMB 常见问题 —— 由 Alphio AI 解答
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Chemomab Therapeutics Ltd. (CMMB) appears to be a good buy right now, trading at $1.38, which is significantly below its 52-week high of $2.99, indicating potential upside. The stock has shown a strong 5-day change of +18.96%, suggesting positive momentum. However, the company has a negative net income with losses reaching -2,165,000 USD in Q2 2026, which presents a risk to consider.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。